AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company markets Feridex I.V., a liver contrast agent; and GastroMARK, an oral contrast agent for delineating the bowel in magnetic resonance imaging (MRI) primarily in Europe and the United States. Its product candidate, Ferumoxytol, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients; and Combidex, an investigational functional molecular imaging agent, consists of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. The company was founded in 1981 as Advanced Magnetics, Inc. and changed its name to AMAG Pharmaceuticals, Inc. in July 2007. AMAG Pharmaceuticals is based in Cambridge, Massachusetts.